Oxford University Hospitals at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Oxford University Hospitals brings 1 presentation to ASH 2026 in New Orleans. Its program spans real-world use of BCMA-targeted bispecific antibodies in myeloma and a red cell disorder that is easy to miss. It covers who develops acquired methemoglobinemia, why it happens and what to do.
| Organization | ASH 2026 Attendance |
|---|---|
Oxford University Hospitals Oxford, United Kingdom | |
NHS teaching hospital trust in Oxford, England, including the John Radcliffe and Churchill hospitals. | Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Talk Acquired Methemoglobinemia: Who, Why, and What to Do Exposures that cause acquired methemoglobinemia, such as dapsone, rasburicase, topical anesthetics and recreational nitrites, and how to diagnose and treat it. |
Instantly find 20 buyers from Oxford University Hospitals
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction